What is the share price of Unichem Laboratories Ltd (UNICHEMLAB) today?
The share price of UNICHEMLAB as on 29th May 2026 is ₹349.35. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Unichem Laboratories Ltd (UNICHEMLAB) share?
The past returns of Unichem Laboratories Ltd (UNICHEMLAB) share are- Past 1 week: -5.77%
- Past 1 month: -5.56%
- Past 3 months: 0.91%
- Past 6 months: -24.38%
- Past 1 year: -42.12%
- Past 3 years: -6.09%
- Past 5 years: 3.53%
What are the peers or stocks similar to Unichem Laboratories Ltd (UNICHEMLAB)?
The peers or stocks similar to Unichem Laboratories Ltd (UNICHEMLAB) include:What is the market cap of Unichem Laboratories Ltd (UNICHEMLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Unichem Laboratories Ltd (UNICHEMLAB) is ₹2459.62 Cr as of 29th May 2026.What is the 52 week high and low of Unichem Laboratories Ltd (UNICHEMLAB) share?
The 52-week high of Unichem Laboratories Ltd (UNICHEMLAB) is ₹666.60 and the 52-week low is ₹278.20.What is the PE and PB ratio of Unichem Laboratories Ltd (UNICHEMLAB) stock?
The P/E (price-to-earnings) ratio of Unichem Laboratories Ltd (UNICHEMLAB) is 9.73. The P/B (price-to-book) ratio is 1.00.Which sector does Unichem Laboratories Ltd (UNICHEMLAB) belong to?
Unichem Laboratories Ltd (UNICHEMLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Unichem Laboratories Ltd (UNICHEMLAB) shares?
You can directly buy Unichem Laboratories Ltd (UNICHEMLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Unichem Laboratories Ltd
UNICHEMLAB Share Price
NSE₹349.351.47% (-5.20)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
UNICHEMLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
UNICHEMLAB Performance & Key Metrics
UNICHEMLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 9.73 | 1.00 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.84 | 6.22 | 0.48% |
UNICHEMLAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
UNICHEMLAB Company Profile
Unichem Laboratories Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs or bulk actives).
SUNPHARMA
PE Ratio
37.61
37.61
1Y Return
5.85%
5.85%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
69.82
69.82
1Y Return
39.53%
39.53%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.17
29.17
1Y Return
5.14%
5.14%
Buy Reco %
62.86
62.86
DRREDDY
PE Ratio
25.87
25.87
1Y Return
4.43%
4.43%
Buy Reco %
51.52
51.52
ZYDUSLIFE
PE Ratio
21.52
21.52
1Y Return
16.54%
16.54%
Buy Reco %
53.57
53.57
UNICHEMLAB Forecast
UNICHEMLAB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
UNICHEMLAB
UNICHEMLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
UNICHEMLAB Income Statement
UNICHEMLAB Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 545.00 | 437.85 | 487.10 | 516.05 | 546.71 | 596.43 | 533.42 | 599.93 | 808.49 | 598.59 | ||||||||||
Operating & Other expenses | 434.60 | 531.97 | 443.19 | 451.87 | 447.57 | 503.48 | 504.11 | 571.04 | 476.39 | 539.80 | ||||||||||
EBITDA | 110.40 | -94.12 | 43.91 | 64.18 | 99.14 | 92.95 | 29.31 | 28.89 | 332.10 | 58.79 | ||||||||||
| Depreciation/Amortization | 31.62 | 27.16 | 32.07 | 32.26 | 30.54 | 29.69 | 31.79 | 31.47 | 31.25 | 30.61 | ||||||||||
| PBIT | 78.78 | -121.28 | 11.84 | 31.92 | 68.60 | 63.26 | -2.48 | -2.58 | 300.85 | 28.18 | ||||||||||
| Interest & Other Items | 5.58 | 4.59 | 4.03 | 4.79 | 6.75 | 5.46 | 6.54 | 8.24 | 7.42 | 9.39 | ||||||||||
| PBT | 73.20 | -125.87 | 7.81 | 27.13 | 61.85 | 57.80 | -9.02 | -10.82 | 293.43 | 18.79 | ||||||||||
| Taxes & Other Items | -0.02 | 3.44 | 5.74 | 2.50 | 4.00 | 4.83 | 1.45 | 1.07 | 29.14 | 7.88 | ||||||||||
| Net Income | 73.22 | -129.31 | 2.07 | 24.63 | 57.85 | 52.97 | -10.47 | -11.89 | 264.29 | 10.91 | ||||||||||
| EPS | 10.39 | -18.37 | 0.29 | 3.50 | 8.22 | 7.52 | -1.49 | -1.69 | 37.54 | 1.55 |
UNICHEMLAB Company Updates
UNICHEMLAB Stock Peers
UNICHEMLAB Past Performance & Peer Comparison
UNICHEMLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Unichem Laboratories Ltd | 9.73 | 1.00 | — |
| Sun Pharmaceutical Industries Ltd | 37.61 | 5.96 | 0.89% |
| Torrent Pharmaceuticals Ltd | 69.82 | 19.67 | — |
| Cipla Ltd | 29.17 | 3.62 | 0.93% |
UNICHEMLAB Stock Price Comparison
Compare UNICHEMLAB with any stock or ETFCompare UNICHEMLAB with any stock or ETF
UNICHEMLAB
UNICHEMLAB Holdings
UNICHEMLAB Shareholdings
UNICHEMLAB Promoter Holdings Trend
UNICHEMLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
UNICHEMLAB Institutional Holdings Trend
UNICHEMLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
UNICHEMLAB Shareholding Pattern
UNICHEMLAB Shareholding Pattern
UNICHEMLAB Shareholding History
UNICHEMLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in UNICHEMLAB
Mutual Funds Invested in UNICHEMLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Unichem Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 7.5373% | Percentage of the fund’s portfolio invested in the stock 0.56% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 61/87 (+6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3316% | Percentage of the fund’s portfolio invested in the stock 1.06% | Change in the portfolio weight of the stock over the last 3 months 0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/33 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 94/130 (-4) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing UNICHEMLAB stock
smallcases containing UNICHEMLAB stock
Looks like this stock is not in any smallcase yet.
UNICHEMLAB Events
UNICHEMLAB Events
UNICHEMLAB Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
UNICHEMLAB Dividend Trend
No dividend trend available
UNICHEMLAB Upcoming Dividends
UNICHEMLAB Upcoming Dividends
No upcoming dividends are available
UNICHEMLAB Past Dividends
UNICHEMLAB Past Dividends
Cash Dividend
Ex DateEx DateAug 1, 2022
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Aug 1, 2022
Cash Dividend
Ex DateEx DateJul 22, 2021
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Jul 22, 2021
Cash Dividend
Ex DateEx DateAug 20, 2020
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Aug 20, 2020
Cash Dividend
Ex DateEx DateJul 18, 2019
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Jul 18, 2019
Cash Dividend
Ex DateEx DateJul 19, 2018
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Jul 19, 2018
UNICHEMLAB Stock News & Opinions
UNICHEMLAB Stock News & Opinions
Articles & Videos
Earnings
Earnings
Unichem Laboratories consolidated net profit declines 79.40% in the March 2026 quarterNet profit of Unichem Laboratories declined 79.40% to Rs 10.91 crore in the quarter ended March 2026 as against Rs 52.97 crore during the previous quarter ended March 2025. Sales declined 2.05% to Rs 575.12 crore in the quarter ended March 2026 as against Rs 587.18 crore during the previous quarter ended March 2025. For the full year,net profit rose 83.86% to Rs 252.84 crore in the year ended March 2026 as against Rs 137.52 crore during the previous year ended March 2025. Sales rose 4.31% to Rs 2201.85 crore in the year ended March 2026 as against Rs 2110.97 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales575.12587.18 -2 2201.852110.97 4 OPM %8.2914.25 -8.3612.55 - PBDT61.7687.49 -29 215.64279.15 -23 PBT31.1557.80 -46 90.52154.59 -41 NP10.9152.97 -79 252.84137.52 84 Powered by Capital Market - Live
6 days agoCapital Market - Live
Corporate
Corporate
Unichem Laboratories to conduct board meetingUnichem Laboratories will hold a meeting of the Board of Directors of the Company on 22 May 2026.
3 weeks agoCapital Market - Live
Earnings
Earnings
Unichem Laboratories consolidated net profit rises 356.85% in the December 2025 quarterNet profit of Unichem Laboratories rose 356.85% to Rs 264.29 crore in the quarter ended December 2025 as against Rs 57.85 crore during the previous quarter ended December 2024. Sales declined 2.24% to Rs 521.17 crore in the quarter ended December 2025 as against Rs 533.09 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales521.17533.09 -2 OPM %8.5916.04 - PBDT49.1692.39 -47 PBT17.9161.85 -71 NP264.2957.85 357 Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Spotlight
Unichem Laboratories' Kolhapur API Facility clears USFDA inspectionThe inspection concluded with five observations, all pertaining to procedural changes, with none related to data integrity. The company said it will submit the required response to the USFDA within the stipulated 15-day period. Unichem Laboratories is engaged in manufacturing of pharmaceutical products. The company's consolidated jumped 83.9% to Rs 45.30 crore on 14.1% increase in net sales to Rs 578.96 crore in Q2 FY26 over Q2 FY25. Shares of Unichem Laboratories rose 0.16% to Rs 374.65 on the BSE. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Unichem Laboratories announces board meeting dateUnichem Laboratories will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Earnings
Unichem Laboratories reports consolidated net loss of Rs 11.89 crore in the September 2025 quarterNet loss of Unichem Laboratories reported to Rs 11.89 crore in the quarter ended September 2025 as against net profit of Rs 24.63 crore during the previous quarter ended September 2024. Sales rose 14.11% to Rs 578.96 crore in the quarter ended September 2025 as against Rs 507.36 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales578.96507.36 14 OPM %11.4310.94 - PBDT78.9159.39 33 PBT47.4427.13 75 NP-11.8924.63 PL Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Earnings
Unichem Laboratories reports standalone net loss of Rs 39.93 crore in the September 2025 quarterNet loss of Unichem Laboratories reported to Rs 39.93 crore in the quarter ended September 2025 as against net profit of Rs 43.37 crore during the previous quarter ended September 2024. Sales declined 18.31% to Rs 356.90 crore in the quarter ended September 2025 as against Rs 436.88 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales356.90436.88 -18 OPM %2.1614.76 - PBDT25.4269.76 -64 PBT-4.6943.37 PL NP-39.9343.37 PL Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Unichem Laboratories to announce Quarterly ResultUnichem Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Unichem Lab's Roha API facility receives EIR reportUnichem Laboratories announced that USFDA has classified the inspection of the company's Roha API facility as Voluntary Action Initiated (VAI) and received the Establishment Inspection Report. Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Earnings
Unichem Laboratories reports consolidated net loss of Rs 10.47 crore in the June 2025 quarterNet loss of Unichem Laboratories reported to Rs 10.47 crore in the quarter ended June 2025 as against net profit of Rs 2.07 crore during the previous quarter ended June 2024. Sales rose 8.95% to Rs 526.60 crore in the quarter ended June 2025 as against Rs 483.34 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales526.60483.34 9 OPM %4.278.31 - PBDT22.7739.88 -43 PBT-9.027.81 PL NP-10.472.07 PL Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 12.41%, vs industry avg of 9.86%
Over the last 5 years, market share increased from 0.47% to 0.51%